Better Buy: Amgen vs. Bristol Myers Squibb

Better Buy: Amgen vs. Bristol Myers Squibb

Both Amgen and BMS have delivered disappointing returns for investors so far this year. Ironically, Amgen's biggest growth driver is Otezla, a drug the company acquired from Celgene last year to pave the way for BMS' acquisition of Celgene. Without Otezla in its lineup, Amgen's total revenue would have declined year over year in the second quarter of 2020.